Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Feb 13:9:212.
doi: 10.3389/fimmu.2018.00212. eCollection 2018.

From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis

Aixin Song  1 , Xinchao Liu  2 , Xiaojie Huang  1 , Kathrine Meyers  3 , Djin-Ye Oh  3 , Jianhua Hou  1 , Wei Xia  1 , Bin Su  1 , Ni Wang  4 , Xiaofan Lu  1 , Huan Xia  1 , Xiaodong Yang  1 , Hui Chen  4 , Hao Wu  1
Affiliations
Meta-Analysis

From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis

Aixin Song et al. Front Immunol. .

Abstract

Background: The World Health Organization (WHO) Consolidated antiretroviral therapy (ART) guidelines set the CD4+ T-cell counts threshold to 500 cells/mm3 in 2013, and 2015 guidelines recommend treating all HIV-infected adults regardless of their CD4+ T-cell counts. To inform the decision-making around ART guidelines for people living with HIV, we systematically reviewed the literature to estimate differences in clinical benefits between individuals starting treatment with baseline CD4+ T-cell counts ≥500 cells/mm3 (early initiation) as compared to <500 cells/mm3 (deferred initiation).

Methods: We systematically searched the electronic databases and abstracts for randomized controlled trials (RCT) and observational studies. Outcomes were mortality, AIDS progression, AIDS or death, immunologic recovery, and virologic suppression. We pooled data across studies and performed analyses of effect sizes.

Results: We identified 13 studies comparing early and deferred treatment. The pooled risk ratio (RR) of mortality of 11 observational studies was 0.90 (95% CI 0.82-0.99), with moderate heterogeneity (I2 = 53%). The pooled RR for progression to AIDS from two observational studies was 0.77 (95% CI 0.47-1.24). Five observational studies found a pooled RR of death or AIDS of 0.94 (95% CI 0.93-0.95). For the outcome of immunologic recovery, defined as CD4+ T-cell counts reaching at least 800 cells/mm3 after ART, one observational study found early initiation of ART had an HR (hazard ratio) of 2.39 (95% CI 1.93-2.96). The pooled RR of viral suppression (a viral load <50 copies/ml) after 9 months from one cohort was 1.04 (95% CI 0.99-1.09).

Conclusion: Mortality risk and risk for AIDS appear to be reduced among people living with HIV with early initiation of ART, based on current WHO guidelines, as compared to those with deferred initiation of ART (<500 cells/mm3).

Keywords: CD4+ T cell; HIV-infected adults; early therapy; meta; mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of selection process for the inclusion of studies.
Figure 2
Figure 2
Forest plots of mortality. CI, confidence interval; DF, degrees of freedom; IV, inverse variance.
Figure 3
Figure 3
Forest plots of subgroup analysis of mortality. CI, confidence interval; DF, degrees of freedom; IV, inverse variance.
Figure 4
Figure 4
Forest plots of AIDS progression. CI, confidence interval; DF, degrees of freedom; IV, inverse variance.
Figure 5
Figure 5
Forest plots of AIDS progression or death. CI, confidence interval; DF, degrees of freedom; IV, inverse variance.
Figure 6
Figure 6
Forest plots of immunologic recovery. CI, confidence interval; DF, degrees of freedom; IV, inverse variance.
Figure 7
Figure 7
Forest plot of virologic suppression. CI, confidence interval; DF, degrees of freedom; IV, inverse variance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eholie SP, Badje A, Kouame GM, N’Takpe JB, Moh R, Danel C, et al. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. AIDS Res Ther (2016) 13:27.10.1186/s12981-016-0111-1 - DOI - PMC - PubMed
    1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N Engl J Med (1997) 337(11):725–33.10.1056/NEJM199709113371101 - DOI - PubMed
    1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 337(11):734–9.10.1056/NEJM199709113371102 - DOI - PubMed
    1. Ford N, Meintjes G, Pozniak A, Bygrave H, Hill A, Peter T, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis (2015) 15(2):241–7.10.1016/S1473-3099(14)70896-5 - DOI - PubMed
    1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 288(2):222–35.10.1001/jama.288.2.222 - DOI - PubMed

Substances